North of Tyne, Gateshead and North Cumbria Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Tuesday 11th January 2022.**

Classification of products:

R = 'RED' drugs for hospital use only
A = 'AMBER' drugs suitable for use under Shared Care arrangements
G+ = 'GREEN PLUS – Drugs normally recommended or initiated by hospital specialist, but where the provision of an information leaflet may be appropriate to facilitate continuing treatment by GPs. Many of these information sheets are in the process of development.
G = 'GREEN' – Drugs where initiation by GPs is appropriate.

1) Requests deferred from previous meetings

Product	Approved	Refused	Deferred	Notes
None				

2) New Requests

Product	Approved	Refused	Deferred	Notes
Syreniring®	✓ G+			Syreniring® is a vaginal contraceptive ring that releases etonogestrel and ethinylestradiol. It contains the same hormones and has the same release characteristics as NuvaRing® which is currently on the formulary. It has been requested as a replacement for NuvaRing® on the grounds that it doesn't need to be stored in the fridge, allowing longer scripts to be issued, and is slightly cheaper. **Decision: Approved**. Syreniring® will replace NuvaRing® on the formulary, as a GREEN plus drug
Pro-Prems® probiotic	✓ R			Pro-Prems® has been requested for the prevention of necrotising enterocolitis (NEC) in pre-term infants. It has recently been reviewed by the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) who gave a conditional recommendation for its use. Costs are higher than Infloran and LaBiNic however it was recognised that the cost of treating NEC is very high. **Decision: Approved**

Recarbio® (imipenem/cilastin and relebactam) IV injection	✓ R			Requested by the microbiologists for the treatment of multi-resistant gram-negative infections. **Decision: Approved**

3) New formulations & extensions to use

Product	Approved	Refused	Deferred	Notes
Doxycycline injection	✓ R			Doxycycline injection (unlicensed in UK) has been requested for off label use as a sclerosing agent for lymphatic malformations in children. It is preferred to bleomycin. Evidence from small retrospective cohort studies suggest that sclerotherapy with doxycycline is effective in the treatment of lymphatic malformations. **Decision: Approved** as a sclerosing agent for lymphatic malformations in children, as a RED drug .
Oxybutynin liquid 1mg/1ml	✓ G			Request to add the 1mg/ml strength of oxybutynin to formulary as a licensed and cost-effective option **Decision: Approved**
Colecalciferol capsules 3200 units	✓ G			Colecalciferol 3200-unit capsules have been requested for formulary inclusion on the grounds that it is priced pro rata with the 800 unit capsule formulation and is more appropriate for patients with malabsorption such as patients who've had bariatric surgery and require higher maintenance doses. **Decision: Approved** for patients with malabsorption such as patients who've had bariatric surgery and require higher maintenance doses.

4) NHS England Specialised Services communications, and interim clinical commissioning policies, noted and endorsed by APC

SSC2294 Clinical Commissioning Policy: Rituximab for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and post-pubescent children.	The formulary will reflect the SSC position
SSC2295: NICE Technology Appraisal Final Appraisal Determination: Selpercatinib for treating advanced thyroid cancer with RET alterations.	The formulary will reflect the SSC position
SSC2296: NICE Technology Appraisal Final Appraisal Determination: nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer	The formulary will reflect the SSC position
SSC2300 National Orbis Drug Access Arrangements – sotorasib as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) exhibiting a KRAS G12C mutation and who have been previously treated with at least 1 prior systemic therapy for advanced NSCLC	The formulary will reflect the SSC position

SSC2301 Clinical Commissioning Policy Anakinra for Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages	The formulary will reflect the SSC position
SSC2302 NICE Technology Appraisal Guidance [TA720] Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma.	The formulary will reflect the SSC position
SSC2303 Clinical Commissioning Policy Vismodegib for adults with either Gorlin syndrome or non-Gorlin syndrome related multiple basal cell carcinomas.	The formulary will reflect the SSC position
SSC2306 Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable	The formulary will reflect the SSC position
SSC2308 mogamulizumab for previously treated mycosis fungoides and Sézary syndrome.	The formulary will reflect the SSC position
SSC2309 fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis.	The formulary will reflect the SSC position
SSC2310 selpercatinib for RET fusion-positive advanced non-small-cell lung cancer	The formulary will reflect the SSC position
SSC2311 osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection	The formulary will reflect the SSC position
SSC2317 Therapeutic Immunoglobulin (Ig)	The formulary will reflect the SSC position
SSC2318 Abatacept for refractory idiopathic inflammatory myopathies (adults and children aged 2 and over)	The formulary will reflect the SSC position
SSC2319 Rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults	The formulary will reflect the SSC position
SSC2320: venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable.	The formulary will reflect the SSC position
SSC2321: pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma.	The formulary will reflect the SSC position
Neutralising monoclonal antibodies (Casirivimab, imdevimab (Ronapreve®) and Sotrovimab) for patients with COVID-19 in line with the NHSE interim commissioning policies	Approved in line with NHSE interim commissioning policies for COVID-19
Molnupiravir	Approved in line with NHSE interim commissioning policies for COVID-19

5) Products considered by NICE

NICE reference	Formulary position	RAG status
HST16 Givosiran for treating acute hepatic porphyria	The formulary will reflect the NICE position	✓ R
TA735: Tofacitinib for treating juvenile idiopathic arthritis	The formulary will reflect the NICE position	✓ R
TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy	The formulary will reflect the NICE position	✓ R
TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer	The formulary will reflect the NICE position	✓ R
TA738:Berotralstat for preventing recurrent attacks of hereditary angioedema	The formulary will reflect the NICE position	✓ R
TA739 Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable	The formulary will reflect the NICE position	✓ R
TA740 Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer	The formulary will reflect the NICE position	✓ R
TA741 Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer	The formulary will reflect the NICE position	✓ R

TA741 Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer	The formulary will reflect the NICE position	✓ R
TA742 Selpercatinib for treating advanced thyroid cancer with RET alterations	The formulary will reflect the NICE position	✓ R
TA743 Crizanlizumab for preventing sickle cell crises in sickle cell disease	The formulary will reflect the NICE position	✓ R
TA744 Upadacitinib for treating moderate rheumatoid arthritis	The formulary will reflect the NICE position	✓ R
TA746 Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer	The formulary will reflect the NICE position	✓ R
TA747 Nintedanib for treating progressive fibrosing interstitial lung diseases	The formulary will reflect the NICE position	✓ R
TA748 Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders	The formulary will reflect the NICE position	✓ R
TA752 Belimumab for treating active autoantibody-positive systemic lupus erythematosus	The formulary will reflect the NICE position	✓ R
TA753 Cenobamate for treating focal onset seizures in epilepsy	The formulary will reflect the NICE position	✓ R
TA754 Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome	The formulary will reflect the NICE position	✓ R
TA755 Risdiplam for treating spinal muscular atrophy	The formulary will reflect the NICE position	✓ R
TA756 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis	The formulary will reflect the NICE position	✓ R
TA757 Cabotegravir with rilpivirine for treating HIV-1	The formulary will reflect the NICE position	✓ R
TA758 Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy	The formulary will reflect the NICE position	✓ R

6) Northern (NHS) Treatment Advisory Group (N-TAG)

No update	

7) Regional Medicines Optimisation Committee (RMOC)

No update	

8) Appeals against earlier decisions by the APC

Product	Approved	Refused	Deferred	Notes
None				

9) Guidelines. http://www.northoftyneapc.nhs.uk/guidance/

Osteoporosis Guideline	Deadline extended to end June 22
Denosumab leaflet	Approved
Liothyronine prescribing guideline	Prices changed to reflect licensing changes
Blood Glucose monitoring guideline	Minor product amendment
NENC Palliative and End of Life symptom control guidelines	Agreed to host on website

Dapagliflozin in HF	Approved
Renal transplant shared care	Approved
7 day prescribing guideline	Update approved
NENC Hepatology network: Abnormal LFT guidelines	Agreed to host on website
SGLT2 diabetes clinical Network Guidance	Minor update approved and on website.

10) Miscellaneous decisions by the APC

Midazolam injection	The NHSE CD accountable officer had noted the prescribing of different strengths of midazolam in primary care other than 10mg/2ml. Discussed with palliative care who agreed that only the 10mg/2ml should be prescribed in primary care. The committee agreed that the 10mg/2ml preparation should be changed to GREEN and first choice for palliative care use in the community. Other strengths should remain GREEN plus and only be used in community on the advice of palliative care.
Collagenase (Xiapex®) for Dupuytren's contracture	Product discontinued so remove from formulary
Hyoscine hydrobromide injection	Hyoscine butylbromide is the first choice for the treatment of respiratory secretions on the grounds that the hydrobromide preparation crosses the blood brain barrier leading to drowsiness. The butylbromide preparation is also safer in renal impairment.
Chloral Hydrate	On the back of the recent MHRA safety alert for the chloral hydrate/betaine that restricts use to maximum of 14 days it was agreed that chloral hydrate will now be a RED drug.
Ciprofloxacin 0.3% eye drop (unlicensed)	The formulary currently suggests that the unlicensed eye drops should be used in the ear, however a licensed eardrop preparation (0.2%) is now available. **Decision:** The 0.2% licensed ear drops will be added to formulary.